Bridget Cole

Bridget Cole was appointed as the Chief Scientific Officer in November 2023, bringing with her a wealth of experience spanning over 25 years in drug discovery and clinical development. Prior to her current role, she served as the Senior Vice President and Head of Chemistry at 1910 Genetics, where she led medicinal chemistry teams in advancing compounds from lead identification through late-stage clinical trials. Her expertise extends across various therapeutic areas, focusing on the development of novel therapies. At Nocion Therapeutics, as the Senior Vice President of Drug Discovery, Cole led lead optimization programs targeting neurogenic inflammation and developed a phase 2 drug candidate for chronic cough. Her career also includes significant roles such as Vice President of Medicinal Chemistry at Axial Biotherapeutics and at Flatley Discovery Lab, where she contributed to biopharmaceutical research and development. Cole is recognized as a co-inventor on 30 issued U.S. patents. She holds a bachelor’s degree in chemistry from Boston University, a Ph.D. in organic chemistry from Brandeis University, and completed her postdoctoral training at Boston College.